April 1 (Reuters) - Maia Biotechnology Inc MAIA.A:
MAIA BIOTECHNOLOGY- PHASE 2 TRIAL THIO-101 EXPANSION UNDERWAY; POTENTIAL FILING IN 2026 FOR ACCELERATED APPROVAL
MAIA BIOTECHNOLOGY- PHASE 3 THIO-104 SET TO BEGIN IN MID-2025; POTENTIAL FILING IN 2026 FOR EARLY FULL APPROVAL
Source text: ID:nBw3b4svwa
Further company coverage: MAIA.A
(((( Reuters.briefs@thomsonreuters.com ;));))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。